BioPharma Credit PLC USD · LSE:BPCP
BioPharma Credit PLC USD — BioPharma Credit — H1 2020 Earnings Presentation
9 slides from BioPharma Credit PLC USD's earnings presentation, September 2020
Slide 1: Debt Capital for the Life Sciences Industry
Debt Capital for the Life Sciences Industry COMPANY PRESENTATION – September 2020 For additional information please email: [email protected] or visit BioPharma Credit’s website at www.bpcruk.com
Slide 2: Disclaimer
Disclaimer . THIS PRESENTATION IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION. THIS PRESENTATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDIC
Slide 3: Disclaimer
Disclaimer This presentation was prepared using the financial information available to the Company as at the date of this presentation. Except where otherwise indicated herein, the information provided in this presentation is based on matters as they exist as of the date of preparation and not as of
Slide 4: Financial Highlights as at June 2020
Financial Highlights as at 30 June 2020 3
Slide 5: Recent Updates
Recent Updates1 7 August Expected repayment of the $150m Novocure loan on or before 18 August 2020 at an expected IRR of 10.2%. (Payment ultimately received on 18 August 2020). GBT’s notice to draw the second tranche of its loan prior to 31 December 2020 which would increase the Company's investment
Slide 6: Major milestones since IPO
Major milestones since IPO1 IPO – $762m gross Placing of Ordinary Issue of C-Shares Placing of Ordinary proceeds including Shares – $154m – $163m gross Shares – $305m $339m of seed assets gross proceeds proceeds gross proceeds March Q2-2017 Q3-2017 Q4-2017 Q1-2018 Q2-2018 Q3-2018 Q4-2018 Q2-2019 Q3-
Slide 7: Portfolio and dividends since IPO
Portfolio and dividends since IPO2 Evolution of the BioPharma Credit portfolio (millions) BPCR Portfolio Composition ($m) $1,600 Collegium • Thirteen investments in the portfolio as of $1,400 $41 30 June / Bio-Pharma IV peaked at seven GBT $150 $175 $155 Sarepta • Largest investment: Sarepta represe
Slide 8: Summary of past transactions
Summary of past transactions Prepaid 23 January 2019 Prepaid 8 September 2020 Prepaid 18 August 2020 Prepaid 30 July 2020 7
Slide 9: Investment Opportunity – Summary
Investment Opportunity – Summary The Life Sciences Debt Market is an Underserved, Large and Growing Opportunity Worldwide $1.1tn industry growing at 6% per annum Large capital needs; global R&D expenditure by pharmaceutical and biotech companies reached $179 billion in 2018, 40% more than in 201